Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;83(3):414-425.
doi: 10.1111/his.14960. Epub 2023 May 24.

Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer

Ayat G Lashen  1   2   3 , Michael S Toss  1   3   4 , Louisa Wootton  1 , Andrew R Green  1   3 , Nigel P Mongan  5   6 , Srinivasan Madhusudan  1   7 , Emad Rakha  1   2   8
Affiliations

Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer

Ayat G Lashen et al. Histopathology. 2023 Sep.

Abstract

Aim: Polo-like kinase-1 (PLK1) plays a crucial role in cell cycle progression, and it is considered a potential therapeutic target in many cancers. Although the role of PLK1 is well established in triple-negative breast cancer (TNBC) as an oncogene, its role in luminal BC is still controversial. In this study, we aimed to evaluate the prognostic and predictive role of PLK1 in BC and its molecular subtypes.

Methods: A large BC cohort (n = 1208) were immunohistochemically stained for PLK1. The association with clinicopathological, molecular subtypes, and survival data was analysed. PLK1 mRNA was evaluated in the publicly available datasets (n = 6774), including The Cancer Genome Atlas and the Kaplan-Meier Plotter tool.

Results: 20% of the study cohort showed high cytoplasmic PLK1 expression. High PLK1 expression was significantly associated with a better outcome in the whole cohort, luminal BC. In contrast, high PLK1 expression was associated with a poor outcome in TNBC. Multivariate analyses indicated that high PLK1 expression is independently associated with longer survival in luminal BC, and in poorer prognosis in TNBC. At the mRNA levels, PLK1 expression was associated with short survival in TNBC consistent with the protein expression. However, in luminal BC, its prognostic value significantly varies between cohorts.

Conclusion: The prognostic role of PLK1 in BC is molecular subtype-dependent. As PLK1 inhibitors are introduced to clinical trials for several cancer types, our study supports evaluation of the pharmacological inhibition of PLK1 as an attractive therapeutic target in TNBC. However, in luminal BC, PLK1 prognostic role remains controversial.

Keywords: ER positive; PLK1; TNBC; breast cancer; luminal; polo-like kinase-1; triple-negative.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gjertsen BT, Schöffski P. Discovery and development of the polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 2015; 29; 11-19.
    1. Vaiopoulos AG, Athanasoula K, Papavassiliou AG. Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges. Biochim. Biophys. Acta 2014; 1842; 971-980.
    1. Markant SL, Esparza LA, Sun J et al. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and polo-like kinases. Cancer Res. 2013; 73; 6310-6322.
    1. Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr. Opin. Cell Biol. 2008; 20; 650-660.
    1. Schmucker S, Sumara I. Molecular dynamics of PLK1 during mitosis. Mol. Cell. Oncol. 2014; 1; e954507.